Therapy for Staphylococcus aureus

Details Therapy for Staphylococcus aureus Therapy for Staphylococcus aureus

1998-07-15

1999-11-30

Woodward, Michael P.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 9, 514 2, A61K 3812, A61K 3814, C07K 900

Patent

active

059942975

ABSTRACT:
The present invention is directed to methods for treating infections caused by Staphylococcus aureus with reduced glycopeptide sensitivity. The invention is preferably practiced with strains of Staphylococcus aureus which are methicillin resistant, such as the Mu5O strain.

REFERENCES:
Abstracts of the 37hu th ICAAC, C-164, Sep. 28-Oct. 1, 1997, p. 74.
J. Antimicrob Chemother, Hiramatsu et al, 1997; 40:135-136.
Ann Intern Med., M.B. Edmond et al, 1996; 124:329-334.
FEMS Microbiology Letters, Noble et al, 93 (1992) 195-198.
New England J. Medicine, Schwalbe et al, 1987, vol. 316, No. 15, pp. 927-931.
J. Clin Microbiol., Veach et al, Sep. 1990, vol. 28, No. 9, pp. 2064-2068.
The Lancet, Jan. 5, 1991, vol. 337, p. 54.
Exp. Opin. Ther. Patents 6(1), 73-75 (1996).
Jones, Ronald N., et al., Antimicrobial Agents and Chemotherapy, 41(2), 488-493 (1996).
Biavasco, Francesca, et al., Antimicrobial Agents and Chemotherapy, 41(10), 2165-2172 (1997).

Affiliated with

Also associated with

Rating

Therapy for Staphylococcus aureus does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapy for Staphylococcus aureus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy for Staphylococcus aureus will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1672477